Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

144.01USD
2 Dec 2016
Change (% chg)

$1.62 (+1.14%)
Prev Close
$142.39
Open
$142.29
Day's High
$144.90
Day's Low
$141.57
Volume
1,229,139
Avg. Vol
1,190,249
52-wk High
$176.85
52-wk Low
$133.64

AMGN.OQ

Chart for AMGN.OQ

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and... (more)

Overall

Beta: 1.16
Market Cap(Mil.): $108,277.90
Shares Outstanding(Mil.): 743.92
Dividend: 1.00
Yield (%): 2.75

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 14.54 42.21 29.87
EPS (TTM): 10.01 -- --
ROI: 11.47 -1.09 14.95
ROE: 25.83 -2.39 16.29

Amgen, Allergan apply for European nod for Avastin biosimilar

Amgen Inc and Allergan Plc said they have submitted an application to the European health regulator seeking approval of their biosimilar version of Roche Holding AG's blockbuster cancer treatment, Avastin.

Dec 02 2016

Supreme Court to consider reviewing delay of biosimilar launch

The Supreme Court will consider early next month whether to grant a petition for review that would require it to interpret the federal law on copycat biologic drugs for the first time, in a case that involves a bid by Apotex Inc to make biosimilar versions of Amgen Inc's white-blood-cell-boosting drugs Neulasta and Neupogen.

Nov 29 2016

Amgen, Novartis aim for big, crowded migraine market after new drug data

Amgen Inc and Novartis said late on Wednesday that episodic migraine sufferers reported fewer debilitating headaches per month after using the companies' investigational drug erenumab, compared to trial participants who got a placebo.

Nov 17 2016

UPDATE 1-Amgen, Novartis aim for big, crowded migraine market after new drug data

Nov 16 Amgen Inc and Novartis said late on Wednesday that episodic migraine sufferers reported fewer debilitating headaches per month after using the companies' investigational drug erenumab, compared to trial participants who got a placebo.

Nov 17 2016

Amgen's migraine drug succeeds in late-stage trial

Amgen Inc said on Wednesday its migraine treatment met the main goal of reducing monthly migraine days in patients with episodic migraine in a second late-stage study.

Nov 16 2016

Amgen's migraine drug succeeds in late-stage trial

Nov 16 Amgen Inc said on Wednesday its migraine treatment met the main goal of reducing monthly migraine days in patients with episodic migraine in a second late-stage study.

Nov 16 2016

Fitch Rates Pfizer's Notes Offering 'A+(exp)'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, November 15 (Fitch) Fitch Ratings has assigned an 'A+(EXP)' rating to Pfizer's senior unsecured notes offering. The net proceeds of the issuance will be used to fund the purchase of the company's 6.2% notes due March 15, 2019. The ratings apply to roughly $42.3 billion of debt outstanding at July 3, 2016. A full list of ratings follows at the end of this release. KEY RATING DRIVERS Little Leverage Flexibility: Despite Fitch

Nov 15 2016

Amgen cholesterol drug reduces artery-clogging plaque in study

NEW ORLEANS Amgen Inc's potent new drug Repatha, when added to statin therapy, not only took "bad" LDL cholesterol down to extremely low levels but caused declines in artery-clogging plaque in a majority of high-risk heart patients after 18 months of treatment, according to data from a clinical trial.

Nov 15 2016

Amgen cholesterol drug reduces artery-clogging plaque in study

NEW ORLEANS, Nov 15 Amgen Inc's potent new drug Repatha, when added to statin therapy, not only took "bad" LDL cholesterol down to extremely low levels but caused declines in artery-clogging plaque in a majority of high-risk heart patients after 18 months of treatment, according to data from a clinical trial.

Nov 15 2016

BRIEF-Janssen reports clinical trial collaboration and supply agreement with Amgen to evaluate Daratumumab in combination with Carfilzomib

* Janssen announces clinical trial collaboration and supply agreement with Amgen to evaluate Daratumumab (darzalex) in combination with Carfilzomib (kyprolis) Source text for Eikon: Further company coverage:

Nov 10 2016

Earnings vs. Estimates